论文部分内容阅读
目的 观察每2周1次大剂量皮下注射人类重组促红细胞生成素(rhEPO)治疗肾性贫血的临床疗效。方法 20例尿毒症合并肾性贫血的血透患者随机分为2组,试验组10例,采用重组人红细胞生成素(益比奥)10000U皮下注射1次/2周治疗,对照组10例,采用重组人红细胞生成素(依倍)2000U皮下注射 3 次/周治疗。治疗期间,监测血常规、血脂、肝肾功能、电解质、血压等指标及病人出现的各种不良反应。结果 试验组与对照组总有效率均为90%,治疗前后白细胞、血小板、血脂、肝肾功能、电解质无明显变化。结论 大剂量 EPO每 2 周 1 次治疗肾性贫血安全可靠、疗效确切,患者依从性好。副作用发生率二者相似。
Objective To observe the clinical effect of high-dose subcutaneous injection of human recombinant erythropoietin (rhEPO) once every two weeks on renal anemia. Methods Twenty patients with uremia and renal anemia were randomly divided into two groups. The experimental group (n = 10) was treated with recombinant human erythropoietin (EPO) at a dose of 1 000 U subcutaneously once per two weeks. The control group (n = 10) Recombinant human erythropoietin (times) 2000U subcutaneous injection 3 times / week treatment. During treatment, monitoring blood, blood lipids, liver and kidney function, electrolytes, blood pressure and other indicators and the patient’s various adverse reactions. Results The total effective rate was 90% in experimental group and control group. There was no significant change of leukocyte, platelet, blood lipid, liver and kidney function and electrolyte before and after treatment. Conclusions The high-dose EPO is safe and reliable once every two weeks for treatment of renal anemia, with definite curative effect and good patient compliance. The incidence of side effects are similar between the two.